Russell Frank Company’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Russell Frank Company’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,258	Closed	-$97K	–	3174
2015 Q4	$97K	Sell	5,258 -3,936	-43%	-$93.8K	﹤0.01%	2810
2015 Q3	$194K	Sell	9,194 -1,846	-17%	-$63.3K	﹤0.01%	2717
2015 Q2	$546K	Sell	11,040 -6,318	-36%	-$378K	﹤0.01%	2552
2015 Q1	$1.36M	Buy	17,358 +14,729	+560%	+$914K	﹤0.01%	1982
2014 Q4	$159K	Hold	2,629	–	–	﹤0.01%	2658
2014 Q3	$112K	Hold	2,629	–	–	﹤0.01%	2644
2014 Q2	$131K	Hold	2,629	–	–	﹤0.01%	2612
2014 Q1	$145K	Hold	2,629	–	–	﹤0.01%	2626
2013 Q4	$177K	Sell	2,629 -14,083	-84%	-$791K	﹤0.01%	2585
2013 Q3	$1.03M	Sell	16,712 -1,379	-8%	-$93.4K	﹤0.01%	2166
2013 Q2	$1.06M	Buy	+18,091	New	+$1.11M	﹤0.01%	2039

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Russell Frank Company's OREX Position: Q1 2016 in Review

Russell Frank Company sold out of Orexigen Therapeutics, Inc. (OREX) in Q1 2016, closing a stake of 5,258 shares — an estimated $97K sold.

Russell Frank Company first reported a position in OREX in Q2 2013 and held it in 11 quarters. The position peaked at $1.36M in Q1 2015. 104 funds tracked by Wall St. Rank hold OREX as of Q1 2016.

Russell Frank Company reported no remaining Orexigen Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Russell Frank Company sold 5,258 Orexigen Therapeutics, Inc. shares in Q1 2016, an estimated $97K.
Russell Frank Company first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 11 quarters.
Russell Frank Company's Orexigen Therapeutics, Inc. position peaked at $1.36M in Q1 2015.
104 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q1 2016.

Based on Russell Frank Company's 13F filing for Q1 2016, filed 29 Apr 2016.